Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
The purpose of this study is to determine the best doses of RAD001 (everolimus) tablets and cisplatin to give to patients who are receiving radiation therapy for head and neck cancer.
Head and Neck Cancer
RADIATION: intensity modulated radiation therapy|DRUG: RAD001 (everolimus) + Cisplatin
To establish the phase II recommended dose of oral RAD001 (everolimus) tablets + weekly intravenous cisplatin given concurrently with radiation therapy., 3 months
To evaluate the safety and tolerability of oral RAD001 + radiation therapy + intravenous cisplatin., 3 months|To estimate the incidence of over-expression of eIF4E in surgical margins by immunohistochemistry (IHC).(only for those subjects who undergo primary surgery), 3 months|To describe the pharmacokinetics of RAD001 administered by PEG (percutaneous gastrostomy) tube., 3 months
The purpose of this study is to determine the best doses of RAD001 (everolimus) tablets and cisplatin to give to patients who are receiving radiation therapy for head and neck cancer.